Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
69.30
-0.86 (-1.23%)
At close: Mar 28, 2025, 4:00 PM
69.29
-0.01 (-0.01%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Novo Nordisk Revenue
In the year 2024, Novo Nordisk had annual revenue of 290.40B DKK with 25.03% growth. Novo Nordisk had revenue of 85.68B in the quarter ending December 31, 2024, with 30.09% growth.
Revenue (ttm)
290.40B DKK
Revenue Growth
+25.03%
P/S Ratio
7.58
Revenue / Employee
3,754,451 DKK
Employees
77,349
Market Cap
305.46B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NVO News
- 23 hours ago - Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal - Market Watch
- 23 hours ago - Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' - CNBC
- 1 day ago - Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
- 1 day ago - BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag - Reuters
- 1 day ago - Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal - Reuters
- 1 day ago - Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action - CNBC
- 1 day ago - Novo shares on track for biggest monthly fall since 2002, investor worries grow - Reuters
- 1 day ago - Resolutions from the Annual General Meeting of Novo Nordisk A/S - GlobeNewsWire